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Abstract
This study aims at assessing NF-kB activity in unstable angina (UA) patients free of symptoms after a 1 year follow-up 
(1YFU). Plasma oxidized low-density lipoproteins (oxLDL), circulating NF-kB, Interleukin 6 (IL-6) and Interleukin 1β 
(IL-1β), high-sensitivity C-reactive protein (hs-CRP), as markers of oxidative stress and inflammation and plasma double-
stranded DNA (ds-DNA), as marker of Neutrophil Extracellular Traps (NETs), were measured in 23 of the previously 
enrolled 27 UA patients. These measurements were compared to the UA data at baseline, and then compared to the data 
derived from the stable angina (SA) and controls (C) enrolled in our previous study (we demonstrated that UA had higher 
levels of NF-kB compared to SA and C). After a 1YFU, UA patients show a significant decrease in NF-kB, IL-6, hs-CRP, 
oxLDL, and ds-DNA plasma levels (p < 0.001) and in IL-1β and White Blood Cells (WBC) (p < 0.005), without differences 
in lipid and glucose assessment. If compared to SA and C, UA after a 1YFU have higher levels of NF-kB, IL-6, ds-DNA, 
WBC, and oxLDL compared to C (p < 0.001), but only IL-6 is higher than SA (p < 0.001). No differences are found in lipid 
and glucose assessment. After a 1YFU, patients with a history of UA improve their oxidative and inflammatory status, such 
as the levels of circulating ds-DNA, without achieving the status of C. They become comparable to SA subjects. This study 
provides new insight on the multiple and apparently contradictory facets of NF-kB in UA and on its possible role as media-
tor in NETs’ formation.
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Introduction
Coronary artery disease is a common complex atheroscle-
rotic pathology associated with substantial morbidity and 
mortality [1]. Unstable angina (UA) is defined as myocar-
dial ischemia at rest or minimal exertion in the absence of 
cardiomyocyte necrosis [2]. Compared with non-ST-ele-
vation myocardial infarction patients, individuals with UA 
do not experience myocardial necrosis, have a substantially 
lower risk of death, and appear to derive less benefit from 
intensified anti-platelet therapy as well as early invasive 
strategy [3, 4]. UA prevalence is expected to be 10% [5] 
among unselected patients admitted with acute chest pain 
to the emergency department (ED).
Nuclear factor kappa B (NF-kB) is the central regulator of 
innate and adaptive response with hundreds of target genes, 
some with pro-inflammatory effects, and some promoting 
cell survival [6]. NF-kB intervenes in the transcription of a 
large number of inflammatory genes coding for cytokines, 
chemokines, and adhesion molecules [7]. NF-kB can be acti-
vated via the canonical and the non-canonical pathway [7]. 
NF-kB is normally held in the cytoplasm in complex with 
the inhibitor-kBα (IkBα). Canonical activation of NF-kB 
involves phosphorylation of IkBα and its proteasome deg-
radation when inflammation occurs [8]. This pathway is 
mainly activated in response to pro-inflammatory stimuli. 
Non-canonical NF-kB signalling is important for the devel-
opment and maintenance of primary and secondary lym-
phoid organs, and adaptive immune responses [7, 8].
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A key role for NF-kB is essential in the pathophysiol-
ogy of myocardial re-perfusion injury, ischemic precon-
ditioning, and UA [9].
Nevertheless, the protective role for NF-kB during 
pathological remodelling of the heart is a source of con-
troversy [9]. This is due to the evidence that NF-kB also 
regulates many different anti-apoptotic factors, such as cel-
lular inhibitors of apoptosis, caspase inhibitors, and Bcl-2 
family members [10].
Cell-free DNA (cf-DNA) is present in small amounts in 
plasma of healthy subjects [11], but it has been reported to 
be elevated in various clinical disorders [12]. It has been 
correlated with the degree of tissue damage, originating 
from necrosis and apoptosis of blood and tissue cells [12]. 
In particular, cf-DNA has been found to be elevated in 
patients with acute coronary syndrome in different studies 
[13, 14] with a prognostic potential [15].
Part of cf-DNA is double-stranded DNA (ds-DNA). Ds-
DNA is a marker of the peculiar process through which 
neutrophils and other cell types expel ds-DNA [16, 17]. 
A fascinating novel explanation of how DNA can actively 
be released under inflammatory conditions has recently 
been discovered [16, 17]. It is an evolutionary and highly 
conserved first-line defence mechanism that allows neu-
trophils to expel their DNA, forming a meshwork of chro-
matin and proteins termed neutrophil extracellular traps 
(NETs) [16, 17]. NETs are the results of a peculiar form 
of cell death that is morphologically characterized by the 
loss of intracellular membranes before the integrity of the 
plasma membrane can be lost. The death of neutrophils 
with NETs formation is called NETosis. The main function 
of NETs is trapping and killing pathogens. Nevertheless, 
recent studies suggest NETs interference in other diseases 
(venous thromboembolism, cancer, autoimmune diseases 
[18–22]) and in atherosclerosis progression [23–26], as 
recently reviewed [27].
We have previously demonstrated [28] that UA patients 
have higher levels of NF-kB compared to stable angina 
(SA) patients, and both have higher levels compared to 
coronary artery disease-free controls (C). The activation 
of NF-kB in circulating cells of UA patients is, at least 
in part, induced by oxidized low-density lipoproteins 
(oxLDL).
The purpose of the present study is to assess NF-kB 
activity and related-circulating molecules in the same UA 
patients now free of symptoms after a 1 year follow-up 
(1YFU).
This study aims also to provide new insight on the mul-
tiple and apparently contradictory facets of NF-kB in UA, 
discussing its deleterious but also its less known survival-
promoting effects. Moreover, a new field of research is pro-




The study was conducted in accordance with the ethical stand-
ards laid down in the Helsinki Declaration of 1975 and its late 
amendments. All participants provided written consent prior 
to commencing the study and the local ethical committee (Uni-
versity of Verona-Azienda Ospedaliera Universitaria Integrata 
Verona) approved the study.
Recruitment of participants
The study population and the measurement methods of NF-kB 
activity and related-circulating molecules have been previously 
described [28]. In addition, exclusion criteria were maintained 
as explained in [28].
As described [28], UA were patients with at least two epi-
sodes of rest anginal pain or one episode lasting more than 
20 min in the previous 48 h preferably, but not necessarily, 
associated with electrocardiographic modifications (T-wave 
inversion, ST-segment depression, and transient ST-segment 
elevation) and a normal value of I-troponin on admission and 
during the first 24 h.
All 27 previously enrolled UA patients were recalled after 
1 year and a blood sample collection was proposed.
Blood sample collection, peripheral blood mononuclear 
cells (PBMC) isolation, oxidized low-density lipoproteins 
(oxLDL) plasma levels, circulating NF-kB, high-sensitivity 
C-Reactive Protein (hs-CRP), lipid assessment, and white 
blood cells (WBC) were evaluated as previously described 
[28]. Circulating Interleukin (IL)-6 and 1-β were tested accord-
ing to the methods described in our previous study [29].
Fluorescent assay Quant-iT™  PicoGreen® ds-DNA Rea-
gent and Kits (Invitrogen) [30] has been used to measure ds-
DNA in serum of UA, SA, C, and UA 1YFU patients.
Statistical analysis
Data were summarized as mean ± standard deviation or 
median (first quartile; third quartile) for normally and non-
normally distributed variables, respectively. Differences values 
were tested using a paired-sample Student’s t test or Wilcoxon 
matched-pair signed-rank test, accordingly to the type of distri-
bution. Statistical analyses were performed with STATA 14.1 
and a 0.05 significance level was adopted.
Results
Twenty-three of the twenty-seven previously enrolled UA 
patients accepted the 1YFU-recall.
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Two patients (males) were excluded for recent coronary 
artery by-pass grafting, one patient (male) was excluded for 
malignancy onset, and one patient (male) denied his consent 
to the 1YFU evaluation. Then, the study setting was com-
posed of 23 UA patients after 1YFU (UA1YFU): 3 females 
and 20 males now free of symptoms related to angina.
Baseline clinical characteristics of the patients are listed 
in Table 1 in [28] and [29].
Nevertheless, a summary table modified from this has 
been re-created: Table 1. Drug therapy was now similar in 
the UA1YFU group: acetylsalicylic acid, angiotensin-con-
verting enzyme inhibitor, β-blocker, and statin.
Table 2 depicts the distribution of concentrations of 
activated circulating NF-kB in PBMC, serum ds-DNA, 
circulating cytokines, OxLDL, lipid and glucose assess-
ment, and hs-CRP and WBC levels of UA patients at base-
line and after a 1YFU. No significant differences in plate-
lets count or in Mean Platelet Volume (MPV) are found 
(210.000 ± 5000  109/L and 91 fL for UA at baseline versus 
200.000 ± 4000  109/L and 93 fL after 1YFU, p 0.03).
NF-kB, IL-6, hs-CRP, oxLDL, and ds-DNA levels are 
significantly lower in UA patients after 1YFU, compared 
to the year before (p < 0.001).
Table 1  Baseline clinical 
characteristics of the groups of 
patients (modified from Table 1 
of [28])
Data are expressed in percent
C controls, UA unstable angina patients, UA1YFU unstable angina patients after a 1 year follow-up, ACE-
I angiotensin-converting enzyme inhibitors, ACS acute coronary syndrome, PCI percutaneous coronary 
intervention, NS not significantly different, / not re-calculated
C (n = 27) SA (n = 29) UA (n = 27) p value UA1YFU (n = 23) p value
Age (years) 66 ± 11 61 ± 9 61 ± 9 NS 62 ± 6 NS
Family history 37% 66% 38% NS 37% /
Smoke 18% 28% 46% NS 0% none < 0.01
Hypercholesterolemia 41% 79% 69% < 0.05 68% /
Hypertension 48% 79% 61% NS 60% /
Diabetes 7% 14% 15% NS 15% /
ACE-I 63% 59% 35% NS 100% < 0.01
Statins 11% 24% 11% NS 100% < 0.01
Aspirin 30% 76% 50% < 0.05 100% < 0.01
Previous ACS None 65% 31% < 0.01 30% /
Previous PCI None 45% 8% < 0.01 7% /
Table 2  Laboratory data of UA 
patients at baseline and after a 
1YFU
Normally distributed continuous variables are expressed as mean ± standard deviation, while non-normally 
distributed variables are presented as median and interquartile range
UA unstable angina patients, UA1YFU unstable angina patients after a 1 year follow-up, NF-kB nuclear fac-
tor kappa B, IL-6 Interleukin 6, IL-1β Interleukin 1β, hs-CRP high-sensitivity C-Reactive protein, oxLDL 
oxidized low-density lipoprotein, LDL low-density lipoprotein, HDL high-density lipoprotein, WBC white 
blood cells, ds-DNA double-stranded DNA
UA baseline (n = 23) LIAlYFU (n = 23) p value
NF-kB ng/μg cell
protein
1.52 (1.54; 1.72) 0.94 (0.35; 1.2) < 0.001
IL-6 pg/mL 6.93 ± 3.43 3.03 ± 1.91 < 0.001
IL-1β pg/mL 0.79 (0.17; 1.37) 0.15 (0.01; 0.28) 0.016
hs-CRP mg/dL 0.98 (0.08; 1.21) 0.42 (0.26; 0.53) < 0.001
oxLDL μg/mL 38.7 ± 4.39 23.1 ± 3.54 < 0.001
LDL mg/dL 140 ± 26 128 ± 27 0.264
HDL mg/dL 44.3 ± 3.6 48.3 ± 11.2 0.145
Cholesterol mg/dL 215 ± 39 202 ± 33 0.302
Triglycerides mg/dL 149 ± 54 160 ± 50 0.819
Glucose mg/dL 101 ± 15 103 ± 46 0.361
WBC count 109/L 9.53 ± 1.8 7.30 ± 1 0.002
ds-DNA ng/mL 23 ± 1 14 ± 1 < 0.001
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IL-1β and WBC levels are significantly lower in UA 
patients after 1YFU compared to the year before (p < 0.005). 
No significant differences are found in routine lipid and glu-
cose assessment.
Figures 1, 2 show, respectively, the levels of NF-kB 
(expressed in ng/μg cell protein) and ds-DNA (expressed in 
ng/mL) in UA patients at baseline and after a 1YFU, com-
pared with SA patients and C.
NF-kB (Fig. 1) and ds-DNA (Fig. 2) levels in UA1YFU 
are significantly lower compared to UA baseline (p < 0.001) 
and not significantly different compared to SA.
All data (for UA baseline, UA1YFU and SA) are signifi-
cantly higher compared to C (p < 0.001).
Figure 3 shows blood concentrations of IL-6 and IL-1β 
in UA at baseline, UA1YFU, SA, and C patients. As previ-
ously reported [29], IL-6 and IL-1β levels were significantly 
higher (p < 0.001) in UA compared to SA and C. UA1YFU 
patients show lower levels of IL-6 (p < 0.001) compared to 
UA at baseline, but significantly higher levels compared to 
SA and C (p < 0.001). UA1YFU patients show lower levels 
of IL-1β (p < 0.001) compared to UA at baseline, but no 
significant differences were found if compared to SA and C.
A significant difference (p < 0.002) is found in WBC in 
UA after a 1YFU (7.30 ± 1  109/L) compared to UA at base-
line (9.53 ± 1.8  109/L). UA1YFU patients have higher WBC 
levels compared both to SA and C (respectively, 6 ± 0.2 and 
6 ± 0.1  109/L; p < 0.005).
A significant difference (p < 0.001) is found in hs-CRP 
in UA after a 1YFU, 0.42 (0.26; 0.53) mg/dL, compared to 
UA at baseline, 0.98 (0.08; 1.21) mg/dL. No significant dif-
ferences in hs-CRP levels are found for UA1YFU patients 
compared to SA and C, respectively, 0.50 (0.08; 1) and 0.43 
(0.08; 0.8) mg/dL.
A significant difference (p < 0.001) is found in oxLDL in 
UA after a 1YFU (23.1 ± 3.54 μg/mL) compared to UA at 
baseline (38.7 ± 4.39 μg/mL). UA1YFU patients have higher 
oxLDL levels compared to C (12.9 ± 4 μg/mL; p < 0.001), 
but no significant differences are found compared to SA 
(23.3 ± 4.4 μg/mL).
Discussion
The main finding of this work is that, after a 1YFU, patients 
with a history of UA improve their inflammatory status, but 
without achieving the status of C, and becoming comparable 
to SA subjects.
The focus of this manuscript is to investigate the role of 
NF-kB in UA patients in their follow-up.
NF-kB has been largely investigated in cardiovascular 
diseases, in particular in ischemic heart disease [9, 10, 28, 
29].
NF-kB is generally well known to worsen cardiac remod-
elling by activating pro-inflammatory pathways to mediate 
cardiac hypertrophy and maladaptive remodelling [31, 32].
Fig. 1  Concentrations of activated circulating Nuclear Factor kappa 
B (NF-kB) in unstable angina (UA) patients at baseline and after a 
1YFU (UA1YFU), compared to stable angina (SA) patients and con-
trol subjects (C). The NF-kB was extracted from peripheral blood 
mononuclear cells (PBMC) derived from the patients. *p < 0.001 vs 
C; ƚp < 0.001 vs SA; §p < 0.001 vs UA1YFU
Fig. 2  Serum ds-DNA of unstable angina (UA) patients at base-
line and after a 1YFU (UA1YFU), compared to stable angina (SA) 
patients and control subjects (C). *p < 0.001 vs C; ƚp < 0,001 vs SA; 
§p < 0.001 vs UA1YFU
Fig. 3  Plasma concentrations of IL-6 and IL-1β in unstable angina 
(UA) patients at baseline and after a 1YFU (UA1YFU), com-
pared to stable angina (SA) patients and control subjects (C). IL-6: 
*p < 0.001 vs C; ƚp < 0.001 vs SA. IL-1β: °p < 0.001 vs C; #p < 0.001 
vs UA1YFU and SA
Internal and Emergency Medicine 
1 3
However, the intriguing point concerns the multi-faceted 
role of NF-kB, in particular its protective role as emerged in 
different studies mentioned below. This fact opens a debate 
about the deleterious and protective role of this transcription 
factor, as recently reviewed [33].
In fact, NF-kB is able to induce the expression of several 
survival proteins including c-IAP1 and 2, and TRAF-1 and 
2 [34–36]. Moreover, NF-kB exerts its protective effects by 
up-regulating the expression of several genes such as Bcl-2 
family members and caspase inhibitors [37].
NF-kB protective action has been shown to be related to 
the cross-talk with heat shock proteins, normally implicated 
in the protection against apoptosis [38–40]. The involvement 
of NF-kB in ischemia re-perfusion injury and protective 
pathways has been observed [41–44]. In this study, NF-kB 
levels are significantly lower in UA patients after a 1YFU 
compared to the year before, and after a 1YFU, they are 
comparable to SA. The activation of NF-kB in circulating 
cells of UA patients is, at least in part, induced by oxLDL, as 
previously demonstrated [28]. The NF-kB persistent activa-
tion, also is lower compared to the acute event (with lower 
levels of oxLDL), can be explained with the double role of 
this transcription factor, regulating its action according to 
the different situations.
Inflammation has a well-established role in coronary 
artery disease [45, 46]. As reported in the previous authors’ 
study [28], the total WBC count and CRP levels are signifi-
cantly higher in UA patients compared to SA and C. After a 
1YFU, UA patients have significantly lower levels of these 
markers compared to their baseline. This fact is important, 
because it opens a debate about the usefulness of CRP as a 
precise follow-up marker. In a prospective multicentre study 
[47], CRP was measured at admission, at hospital discharge 
and 1 month later in consecutive patients hospitalized for 
acute coronary syndrome. This study aimed to determine 
whether there was a clinical prognostic utility for measuring 
CRP following an acute coronary episode. In conclusion, 
the study did not support the clinical use of CRP because of 
the lack of substantial predictive ability (death, myocardial 
infarction, or UA) of this marker. Nevertheless, CRP is con-
sidered the principal marker able to predict short- and long-
term outcome in patients with acute coronary syndrome, 
with several studies supporting this notion [48–50].
Then, the discussion could be driven toward a particular 
field of research with the aim of including a proposal of the 
possible role of NF-kB as mediator in NETs’ formation.
According to the results of this study, patients with UA 
at baseline have significantly higher levels of circulating ds-
DNA compared to SA and C. After 1YFU, the UA patients 
became comparable to SA.
To our knowledge, this is the first study that after a 1YFU 
compares ds-DNA in UA at baseline to SA and C. Sus-
tained levels of ds-DNA in UA1YFU and SA patients might 
indicate that also even without symptoms, these groups of 
patients are not comparable to healthy subjects. This fact 
could be revelatory of ongoing tissue damage, but also of 
the activation of neutrophils in forming NETs. Moreover, 
UA1YFU patients have higher WBC levels compared both 
to SA and C. The increased number and the stimulation of 
neutrophils (represented by ds-DNA) might be driven by 
NF-kB. In fact, a recent study [51] has shown that NF-kB is 
involved in the generation of NETs. The authors demonstrate 
that acetylsalicylic acid (ASA) and NF-kB inhibitors (using 
two structurally specific inhibitor of IkBα phosphorylation) 
have an inhibitory effect on NETs formation in vitro. The 
effects of ASA are not only related to cyclo-oxygenase acety-
lation, but also include inhibition of NF-kB activation [52]. 
A previous study [53] shows that the stimulation of neutro-
phils induces both the nuclear accumulation of NF-kB/Rel 
proteins and the concomitant degradation of IkBα.
On the basis of these studies, Lapponi et al. [51] conclude 
that this major inflammatory factor is involved in the inflam-
matory response mediated by NETs.
Ds-DNA has cytotoxic and pro-thrombotic effects [54], 
creating a link between inflammation and coagulation. The 
study by Borissoff [23] clarifies the relationships between 
extracellular DNA formation, coronary atherosclerosis, and 
the presence of a pro-thrombotic state. The study reveals 
that markers of NETosis (ds-DNA, nucleosomes, citrul-
linated histone H4, and MPO-DNA complexes) are inde-
pendently associated with the severity of coronary artery 
disease, a pro-thrombotic state, and also the occurrence of 
major adverse cardiac events. The study suggests that NETs 
formation might contribute to atherosclerosis progression.
The previous histological studies have shown the pres-
ence of NETs in the luminal portion of mouse and human 
atherosclerotic lesions [24, 25]. In a very recent study [26], 
coronary thrombarterectomies derived from patients with 
ST-elevation acute coronary syndrome (undergoing primary 
percutaneous coronary intervention) were analyzed. In the 
culprit lesion site, NETs burden positively correlate with 
infarct size and negatively with ST-segment resolution. In 
fact, nucleosomes, ds-DNA, neutrophil elastase, myeloper-
oxidase, all markers of NETosis are found to be increased 
in the culprit lesion site [26].
Inflammation contributes to all phases of atherosclerosis 
[55]. Interleukins, in particular, IL-6 and IL-1β, are critical 
mediators of the systemic inflammatory response [56, 57].
Secretion of cytokines by inflammatory cells is a major 
driver of pathogenesis in UA [58]. As previously reported 
by the authors [29], UA patients exhibit greatly enhanced 
plasma concentrations of IL-6 and IL-1β compared to SA 
and C. As discussed [29], this fact might be related to the 
effect of circulating oxLDL.
Now, after 1YFU, UA patients show lower levels of IL-6 
compared to UA at baseline, but significantly higher levels 
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compared to SA and C. UA1YFU patients show lower levels 
of IL-1β compared to UA at baseline, but no significant dif-
ferences are found if compared to SA and C. Thus, the trend 
of these molecules is quite different.
It is well known that interleukin-1 (IL-1) plays a particu-
larly prominent role in atherothrombosis [59]. In addition, 
a complex of intracellular proteins, known as the nucleo-
tide-binding leucine-rich repeat-containing pyrin receptor 
3 (NLRP3) inflammasome, activates caspase-1 or IL-1β 
converting enzyme, the protease that produces active IL-1β 
from its inactive precursor [60–63]. Several exogenous “dan-
ger signals” trigger the inflammasome including crystalline 
compounds. It has been shown that the NLRP3 inflamma-
some is critical for production of active IL-1β responses 
not only by bacteria, crystalline uric acid, and crystalline 
pyrophosphate, but also to cholesterol crystals and mini-
mally modified LDL cholesterol [64].
These facts were the basis of the well-known CANTOS 
study [65] with Canakinumab.
This fact leads to some considerations, trying to give a 
link between these cytokines, NETs, and NF-kB regulation.
In a mouse model of atherosclerosis [66], cholesterol 
crystals act both as priming and danger signals for IL-1β 
production. Cholesterol crystals trigger neutrophils to 
release NETs.
In addition, IL-6 is a potent NETs inducer, as previously 
demonstrated [67]. Nevertheless, this cytokine is principally 
known for a precise role in atherosclerosis [68]. Large quan-
tities of IL-6 were found in human atherosclerotic plaques 
[69]. In particular, IL-6 can promote the occurrence of ath-
erosclerosis development and plaque rupture [68, 69].
Different studies [70–72] show that serum IL-6 of acute 
myocardial infarction patients is significantly higher com-
pared to UA patients. The levels in UA are significantly 
higher compared to SA. These results agree with the result 
of the current study. The potential causal role of IL-6 in 
atherothrombosis has been suggested by its selective expres-
sion in macrophages in murine and human atheroma [69, 
73, 74]. IL-6 is highly up-regulated at the site of the cor-
onary occlusion. It can be produced by cardiac myocytes 
under condition of local hypoxia in the viable border zone 
of re-perfused infarction. [75]. IL-6 is considered a predic-
tor of high-risk coronary anatomy, as defined by coronary 
computed tomography angiography [76]. At least, circulat-
ing IL-6 has been shown to be associated with the thin-cap 
fibroatheroma, that is the lesion with the highest potential 
for plaque rupture [77, 78]. All these data suggest that IL-6 
levels might correlate with the instability of the atheroscle-
rotic plaque. In fact, IL-6 has a stimulatory effect on smooth 
muscle cells proliferation [77].
Il-6 is regulated by NF-kB [79, 80]. The hallmark of vas-
cular NF-kB activation is the production of IL-6, whose local 
role in vascular inflammation has been reviewed [79].The 
ultimate consequence of NF-kB signalling is the activation of 
inflammatory genes including adhesion molecules and chemo-
taxins. However, clinically, the hallmark of vascular NF-kB 
activation is the production of IL-6 [79].The same trend in UA 
at baseline, UA1YFU, SA for IL-6, and NF-kB may reflect this 
fact. In particular, the higher levels in UA1YFU compared to 
SA might correlate with the plaque instability that led to the 
UA condition the year before.
All the markers considered in this work are affected by 
therapy, of course. There is a large knowledge about this fact 
[26, 29, 45, 50–52, 65]. The small sample of patients in the 
current study does not allow the exact contribution of each 
drug in the influence of the final condition. However, the find-
ing that despite complete therapy (according to the current 
guidelines for UA), UA1YFU patients do not reach the condi-
tion of C; this fact itself means that the pathology itself makes 
the difference.
Study limitations
The main limitation of this study is the lack of complete collec-
tion of NETosis markers other than ds-DNA. This fact makes 
the authors’ considerations partially elusive for the moment.
Moreover, several biological and methodological hurdles 
have been identified in cf-DNA testing, as reviewed [81] (dif-
ferent testing methods, great variability of the levels in the 
healthy population, etc.). Nevertheless, up to now, no precise 
data are available about ds-DNA. It is reasonable that similar 
considerations could also be done for these DNA fragments.
The absence of a follow-up sampling in the SA and C is 
a further consistent limitation of the study.
However, the strength of the study is underlining the new 
overview of the role of NF-kB, as a protective factor con-
nected with NETosis in UA. These notions must be elevated 
to a new degree when considering the enormously compli-
cated interacting networks that explain the complex and not 
fully investigated mechanisms that link immunity, inflamma-
tion, and cardiovascular diseases. There are very few data 
in the literature about the hypothesis that NF-kB may act 
as the mediator of NETs’ formation. A very recent paper, 
in a different context (Dermatology and Wound healing), 
analyzes this fact. NETs’ scaffold recognized by Toll-Like 
Receptor 9 (TLR 9) is able to activate the NF-kB pathway. 
NETs’ stimulation rapidly induces a dose dependent NF-kB 
activation and such signalling pathway modulates keratino-
cytes proliferation [82].
Conclusions
After a 1YFU, patients with a history of UA improve their 
inflammatory status, but without achieving the status of C, 
and becoming comparable to SA subjects.
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In conclusion, the persistent activation of NF-kB in these 
patients might also be considered a conceivable solution 
to maintain an innate immunity response, as NETosis is. 
NF-kB activation and NETs formation are, therefore, similar 
to a double-edged sword, acting not only as an effective first-
line defence mechanism, but also leading to organ failure 
and death if the process is uncontrolled.
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